By SPC News Staff
The FDA granted a new indication for ibrutinib (Imbruvica, Pharmacyclics/Janssen) for the treatment of adult patients with chronic graft-versus-host disease (cGVHD) after failure with one or more lines of systemic therapy.
With this approval, ibrutinib becomes the first and only therapy specifically approved for adults with cGVHD, a serious and debilitating potential consequence of a stem cell or bone marrow transplant. Ibrutinib is a first-in-class Bruton’s tyrosine